Musa Yilmaz, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a Phase I/II trial investigating the efficacy of the combination of quizartinib plus decitabine and venetoclax in patients with FLT3-mutated acute myeloid leukemia (AML). Dr Yilmaz first provides some background information on the patients enrolled in this trial, and then discusses the response rates and toxicities observed. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
